These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 11156210

  • 1. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
    Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F.
    Clin Cancer Res; 2000 Dec; 6(12):4610-7. PubMed ID: 11156210
    [Abstract] [Full Text] [Related]

  • 2. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
    Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF.
    Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
    [Abstract] [Full Text] [Related]

  • 3. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
    Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF.
    Clin Cancer Res; 2001 Oct; 7(10):3025-30. PubMed ID: 11595690
    [Abstract] [Full Text] [Related]

  • 4. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF.
    Cancer; 2004 Apr 01; 100(7):1365-73. PubMed ID: 15042669
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R.
    Clin Cancer Res; 2000 Jan 01; 6(1):50-6. PubMed ID: 10656431
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
    Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA.
    Clin Cancer Res; 2006 Mar 01; 12(5):1570-6. PubMed ID: 16533783
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
    Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN.
    Clin Cancer Res; 2002 May 01; 8(5):1073-9. PubMed ID: 12006521
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D, Tong F, Cao Y, Liu P, Zhou B, Liu H, Qiao X, Zhang J.
    Zhonghua Zhong Liu Za Zhi; 2002 May 01; 24(3):303-5. PubMed ID: 12515634
    [Abstract] [Full Text] [Related]

  • 14. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R, Osaki A, Toge T.
    Oncol Rep; 2003 May 01; 10(1):145-50. PubMed ID: 12469161
    [Abstract] [Full Text] [Related]

  • 15. Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer.
    Arnedos M, Sutherland S, Ashley S, Smith I.
    Breast Cancer Res Treat; 2008 Nov 01; 112(1):1-4. PubMed ID: 18060493
    [Abstract] [Full Text] [Related]

  • 16. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2009 Jun 15; 15(12):4234-41. PubMed ID: 19509181
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro.
    Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):665-72. PubMed ID: 16534615
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.